On July 21, 2010
Safety Concerns May Sink Both Vivus and Its Obesity Drug Qnexa
Vivus (VVUS) swung for the fences — and missed — as an FDA advisory board voted against recommending its anti-obesity drug Qnexa for approval, basing their decision largely on an absence of long-term safety data. Does the small biotech have
…
0 Comments